Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros Inc. reports developments in water technology for medical and commercial markets, with emphasis on point-of-use filtration, waterborne pathogen risk reduction, and water management support. Company news commonly covers quarterly financial results, programmatic revenue trends, service offerings, customer education, and product adoption across healthcare facilities and other complex buildings.
Updates also include expansions of Nephros' water safety capabilities, regional market initiatives, and the Nephros Water Institute, an education effort focused on water quality, infection prevention, regulatory readiness, and emergency preparedness for compromised water events.
Nephros announced findings from a study utilizing its SequaPath microbial screening system, evaluating 88 water samples across four US regions, highlighting the necessity of assessing microbial community structures in buildings previously unoccupied due to COVID-19.
Bacterial counts in stagnant water samples from unoccupied buildings were found to be up to 1,400 times higher than those in occupied spaces. The study revealed that over 50 bacterial genera, which may include pathogens, were detected in about 60% of unoccupied samples, emphasizing that tests focusing solely on Legionella are insufficient for ensuring safety.
Nephros, a commercial-stage company specializing in high-performance water purification and pathogen detection systems, announces its participation in the upcoming Zooming with LD event on July 23rd, 2020, at 11:00 AM ET. Daron Evans, President & CEO, and Andy Astor, COO & CFO, will present and address investor inquiries. Interested parties can register for the virtual presentation through the provided link. Nephros's products, including ultrafilters and pathogen detection systems, enhance infection control and water quality across various markets, including healthcare and food service.
Nephros anticipates $1.6 million in net revenues for Q2 2020, marking a 33% decline compared to the same quarter in 2019. The company ended the quarter with approximately $7.0 million in cash. This revenue decrease halted a four-year growth streak, largely attributed to COVID-19 challenges. CEO Daron Evans expressed optimism about future growth, citing rising focus on pathogens beyond COVID-19 and promising products like PluraPath, SequaPath, and DialyPath. However, there are risks related to delays in customer acquisitions due to potential new COVID-19 restrictions.
Nephros, a water purification and pathogen detection company, announced its inclusion in the Russell Microcap® Index effective June 29, 2020. This recognition is seen as a significant milestone in its growth trajectory, expected to enhance Nephros' visibility and expand its shareholder base. Inclusion in the Russell index supports the company's stature among institutional investors, with approximately $9 trillion in assets benchmarked against Russell's indexes. The company develops ultrafilters used in hospitals and pathogen detection systems for real-time water quality monitoring.
Nephros, Inc. (Nasdaq: NEPH) announced its participation in the Virtual Summer Summit scheduled for June 9, 2020, at 10:55 AM ET. Andy Astor, the company's COO & CFO, will present and field questions from investors. Nephros specializes in high-performance water purification products and pathogen detection systems for medical and commercial markets, including hospitals and dialysis centers. Interested parties can access the webcast presentation and register for the event via Nephros's official links.
Nephros, Inc. (Nasdaq: NEPH) has announced a change to its 2020 Annual Meeting of Stockholders, which will now be conducted via webcast on May 21, 2020, at 9:00 a.m. Eastern Time, due to public health concerns related to the coronavirus. Stockholders of record as of March 25, 2020, are encouraged to participate and vote online. After the meeting, management will provide business overviews and a Q&A session. Stockholders can submit questions through the virtual meeting platform.
Nephros reported a 43% increase in net revenue, reaching $2.5 million for Q1 2020, up from $1.8 million in Q1 2019. The company's net loss improved by 19%, totaling $1.1 million. Adjusted EBITDA showed a 7% improvement, at ($0.8 million). Gross margins increased to 59% from 56%. R&D expenses decreased by 26% to $0.6 million, while SG&A expenses rose by 30%, totaling $1.9 million. Nephros held $9.0 million in cash and equivalents as of March 31, 2020.
Summary not available.